ITUS (ITUS) Stock Price, News & Analysis

Company Overview

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Key Stats

• Today's Range: $4.61 to $4.76
• 50-Day Range: N/A
• 52-Week Range: $1.83 to $6.43
• Volume: 69,859 shs
• Average Volume: 134,373 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ITUS Stock Analysis - Frequently Asked Questions

How were ITUS's earnings last quarter?

ITUS Co. (NASDAQ:ITUS) issued its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) EPS for the quarter.

What other stocks do shareholders of ITUS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ITUS investors own include Synergy Pharmaceuticals (SGYP), Galectin Therapeutics (GALT), Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN) and Anixa Biosciences (ANIX).

Company Calendar

• Last Earnings: 3/09/2018
• Today: 7/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Patent Owners & Lessors
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ITUS
• CIK: 715446
• Web: www.ituscorp.com
• Phone: (408) 708-9808
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A